EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Management of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey

Ilaria Meynet iD, Jarkko Karvonen iD, Giuseppe Boriani iD, Diego Penela iD, Michal Mazurek iD, Giacomo Mugnai iD, Rui Providencia iD, Piotr Futyma iD, Andreas Metzner iD, Julian K R Chun iD, Laura Perrotta iD

Europace · 2025

DOI: 10.1093/europace/euaf284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Europace, 2025. Verfasst von Ilaria Meynet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Ospedale di Rivoli, Strada Rivalta 29, 10098, Rivoli (Torino), Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Practice Patterns, Physicians', Anticoagulants, Defibrillators, Implantable. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Device-detected subclinical atrial fibrillation (DDAF) is increasingly documented either with implantable cardiac electronic devices (CIED) or with consumer-based mobile or wearable monitors. We aimed to investigate phisician's reaction to DDAF, which management is still matter of debate.

Methods

This is a physician-based survey with 24 multiple-choice questions.

Results

A total of 222 physicians from 46 countries responded the survey. DDAF is frequent, occurring in >10% of CIEDs follow-up for 37% of respondents. Oral anticoagulation is prescribed according to CHA2DS2-VA and AF duration; 34% of the respondents initiate anticoagulation with AF >24 h, 26% with AF >6 h, and 15% with AF >5–6 min. Respondents from non-European countries and Mediterranean Europe are more likely to prescribe diagnostic exams and therapy than respondents from North Europe. Systematic long-term AF screening with implantable loop recorder (ILR) after cryptogenic stroke ranges from 43 ± 27% of ILR implanted for that purpose in Mediterranean countries to 10 ± 20% in North Europe. The majority of responders recommends the use of consumer-based devices to screen for AF mainly in specific situations (undiagnosed palpitations, ischaemic stroke, or AF burden monitoring) and not routinely, just according to CHA2DS2-VA or age.

Conclusion

AF screening is not routinely performed, either in primary or secondary prevention of stroke. Device-detected AF is not uncommon and generally managed based on thromboembolic risk and duration of episodes; the cut-offs of AF duration, global burden, and number of episodes are yet to be determined in terms of role and clinical value. Clinicians’ approaches to subclinical AF remain heterogeneous.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPractice Patterns, Physicians'AnticoagulantsDefibrillators, ImplantableStrokeWearable Electronic DevicesPacemaker, ArtificialElectrocardiography, AmbulatoryHumansEuropeHealth Care SurveysAsymptomatic DiseasesRisk Factors

Stichwörter der Autor:innen

Atrial fibrillationConsumed-based devicesEHRA SurveyImplantable devicesOral anticoagulationScreening

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Division of Cardiology, Ospedale di Rivoli, Strada Rivalta 29, 10098, Rivoli (Torino), Italy.
  • Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland.
  • Cardiology Division, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41125 Modena, Italy.
  • Humanitas Research Hospital IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Via Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy.
  • 1st Department of Cardiology and Angiology, Silesian Center for Heart Diseases, ul. Skłodowskiej Curie 9, 41-800 Zabrze, Poland.

ORCID-Profile: Ilaria Meynet, Jarkko Karvonen, Giuseppe Boriani, Diego Penela, Michal Mazurek, Giacomo Mugnai, Rui Providencia, Piotr Futyma, Andreas Metzner, Julian K R Chun, Laura Perrotta

Zitieren

APA

Meynet, I., Karvonen, J., Boriani, G., Penela, D., Mazurek, M., Mugnai, G., Providencia, R., Futyma, P., Metzner, A., Chun, J. K. R., & Perrotta, L. (2025). Management of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey. Europace. https://doi.org/10.1093/europace/euaf284

Vancouver

Meynet I, Karvonen J, Boriani G, Penela D, Mazurek M, Mugnai G, et al. Management of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey. Europace. 2025. doi:10.1093/europace/euaf284

BibTeX
@article{Meynet2025,
  author = {Meynet, Ilaria and Karvonen, Jarkko and Boriani, Giuseppe and Penela, Diego and Mazurek, Michal and Mugnai, Giacomo and Providencia, Rui and Futyma, Piotr and Metzner, Andreas and Chun, Julian K R and Perrotta, Laura},
  title = {Management of device-detected subclinical atrial fibrillation: a European Heart Rhythm Association survey},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf284}
}
Kostenlos starten →